Triplet Regimen Boosts Survival in Metastatic Melanoma, but at a Cost Triplet Regimen Boosts Survival in Metastatic Melanoma, but at a Cost

For patients with metastatic melanoma, triplet therapy with atezolizumab and vemurafenib plus cobimetinib provides significant survival benefits, but the regimen may not be cost-effective, researchers say.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news